Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 41-48

  Barr, Martin P ^a   Bouchier Hayes, David J ^a   Harmey, Judith H ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Apoptosis; Hypoxia; Phosphatidylinositol 3 kinase; Survival; Vascular endothelial growth factor

Indexed keywords

NEUROPILIN 1; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; VASCULOTROPIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST ADENOCARCINOMA; BREAST TUMOR; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 38749097333     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.41     Document Type: Article

References (43)

1. Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289, 1997.
2. Nordsmark M, Overgaard M and Overgaard J: Pretreatment of oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39, 1996.
3. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR and Dewhirst MW: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996.
4. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
5. Airley RE, Phillips RM, Evans AE, et al: Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkytating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol 26: 1477-1484, 2005.
6. Yokoi K and Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10: 2299-2306, 2004.
7. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2004.
8. Jain RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9: 253-266, 1990.
9. Van den Eynden GG, Van der Auwere I, Van Laere SJ, et al: Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer 93: 1128-1136, 2005.
10. Koshikawa N, Iyozumi A, Gassmann M and Takenaga K: Constitutive upregulation of hypoxia-inducible factor-1-alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxia exposure. Oncogene 22: 6717-6724, 2003.
11. Dachs GU and Stratford IJ: The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 74: 126-132, 1996.
12. Rofstad EK and Danielsen T: Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 80: 1697-1707, 1999.
13. Asano M, Yukita A and Suzuki H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 90: 93-100, 1999.
14. Kanai T, Konno H, Tanaka T, et al: Anti-tumor and anti-metastatic effects of human vascular endothelial growth factor neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77: 933-936, 1998.
15. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
16. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D and Johnson RS: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59: 1592-1598, 1999.
17. Dias S, Shmelkov SV, Lana G and Rafii S: VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99: 2532-2540, 2002.
18. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G and Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61: 5736-5740, 2001.
19. Pidgeon GP, Barr MP, Harmey JH, Foley DA and Bouchier-Hayes DJ: Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85: 273-278, 2001.
20. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM and Polverini PJ: Upregulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumour growth. Cancer Res 61: 2183-2188, 2001.
21. Hutchings H, Ortega N and Plouet J: Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration and survival through integrin ligation. FASEB J 17: 1520-1522, 2003.
22. Cai J, Ahmad S, Jiang WG, Huang J, Kontos CD, Boulton M and Ahmed A: Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52: 2959-2968, 2003.
23. Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, Bouchier-Hayes DJ, et al: A peptide corresponding to the neuropilin-1 binding site on VEGF(165) induces apoptosis of neuropilin-l-expressing breast tumour cells. Br J Cancer 92: 328-333, 2005.
24. Andjelkovic M, Alessi DR, Meier R, et al: Role of translocation in the activation and function of protein kinase B. J Biol Chem 272: 31515-31524, 1997.
25. Stokoe D, Stephens LR, Copeland T, et al: Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B. Science 277: 567-570, 1997.
26. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB and Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261-269, 1997.
27. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
28. Nor JE, Christensen J, Mooney DJ and Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384, 1999.
29. Katoh O, Takahashi T, Oguri T, et al: Vascular endothelial growth factor inhibits apoptotic death in haematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL-1 acting as an antiapoptotic factor. Cancer Res 58: 5565-5569, 1998.
30. Beierle EA, Strande LF and Chen MK: VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 37: 467-471,2002.
31. Chung J, Yoon S, Datta K, Bachelder RE and Mercurio AM: Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on α6B1 integrin in breast carcinoma cells. Cancer Res 64:4711-4716, 2004.
32. Nunez G and Del Paso L: Linking extracellular survival signals and the apoptotic machinery. Curr Opin Neurobiol 8: 613-618, 1998.
33. Fujisawa H and Kitsukawa T: Receptors for collapsin/semaphorins. Curr Opin Neurobiol 8: 587-592, 1998.
34. Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998.
35. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S and Klagsbrun M: Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and anti-tumor activity. Proc Natl Acad Sci USA 97: 2573-2578, 2000.
36. Bachelder RE, Wendt MA and Mercurio AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62: 7203-7206, 2002.
37. Gerber HP, Malik AK, Solar GP, et al: Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954-958, 2002.
38. Marti HH and Risau W: Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 95: 15809-15814, 1998.
39. Ding H, Wu X, Roncari L, Lau N, Shannon P, Nagy A and Guha A: Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer 88: 584-592, 2000.
40. He Z and Tessier-Lavigne M: Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90:739-751, 1997.
41. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ and Ginty DD: Neuropilin is a semaphorin III receptor. Cell 90: 753-762, 1997.
42. Takahashi T, Fournier A, Nakamura F, et al: Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99: 59-69, 1999.
43. Oosthuyse B, Moons L, Storkebaum E, et al: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131-138, 2001.